Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Share-based Compensation (2016 - 2025)

Assembly Biosciences has reported Share-based Compensation over the past 11 years, most recently at $1.5 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $1.5 million for Q4 2025, up 94.54% from a year ago — trailing twelve months through Dec 2025 was $4.7 million (up 49.9% YoY), and the annual figure for FY2025 was $4.7 million, up 49.9%.
  • Share-based Compensation for Q4 2025 was $1.5 million at Assembly Biosciences, down from $1.7 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ASMB hit a ceiling of $2.0 million in Q4 2022 and a floor of -$286000.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $1.3 million (2022), compared with a mean of $1.2 million.
  • Biggest five-year swings in Share-based Compensation: tumbled 105.81% in 2021 and later surged 604.55% in 2022.
  • Assembly Biosciences' Share-based Compensation stood at $1.9 million in 2021, then increased by 3.5% to $2.0 million in 2022, then plummeted by 52.36% to $959000.0 in 2023, then decreased by 21.69% to $751000.0 in 2024, then skyrocketed by 94.54% to $1.5 million in 2025.
  • The last three reported values for Share-based Compensation were $1.5 million (Q4 2025), $1.7 million (Q3 2025), and $834000.0 (Q2 2025) per Business Quant data.